Fresh off $598M deal with Novo Nordisk, a Japanese stem cell company is on its way to the clinic with a different approach to treating heart failure

Nicole DeFeudis

Editor

A common approach to treating heart failure with induced pluripotent stem cells involves grafting sheets of cells onto the surface of the heart to improve …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fresh off $598M deal with Novo Nordisk, a Japanese stem cell company is on its way to the clinic with a different approach to treating heart failure

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Fresh off $598M deal with No­vo Nordisk, a Japan­ese stem cell com­pa­ny is on its way to the clin­ic with a dif­fer­ent ap­proach to treat­ing heart fail­ure

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Fresh off $598M deal with Novo Nordisk, a Japanese stem cell company is on its way to the clinic with a different approach to treating heart failure